CM
ZYNE

Caption Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Caption Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-218,000
Closed -$734K – 1325
2020
Q2 		$734K Buy
218,000
+208,800
+2,270% +$987K 0.02% 603
2020
Q1 		$36K Hold
9,200
– – ﹤0.01% 802
2019
Q4 		$54K Buy
+9,200
New +$62.9K ﹤0.01% 775

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Caption Management's ZYNE Position: Q3 2018 in Review

Caption Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2018, closing a stake of 6,000 shares — an estimated $59K sold.

Caption Management first reported a position in ZYNE in Q1 2018 and held it in 2 quarters. The position peaked at $59K in Q2 2018. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2018.

  • Caption Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2018 after selling out during the quarter.
  • Caption Management sold 6,000 Zynerba Pharmaceuticals, Inc shares in Q3 2018, an estimated $59K.
  • Caption Management first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2018 and held it in 2 quarters.
  • Caption Management's Zynerba Pharmaceuticals, Inc position peaked at $59K in Q2 2018.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2018.

Based on Caption Management's 13F filing for Q3 2018, filed 14 Nov 2018.